|
1
|
Carlin BI and Andriole GL: The natural
history, skeletal complications, and management of bone metastases
in patients with prostate carcinoma. Cancer. 88(Suppl): 2989–2994.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Karantanos T, Corn PG and Thompson TC:
Prostate cancer progression after androgen deprivation therapy:
Mechanisms of castrate resistance and novel therapeutic approaches.
Oncogene. 32:5501–5511. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Friedlander TW, Ngo VT, Dong H,
Premasekharan G, Weinberg V, Doty S, Zhao Q, Gilbert EG, Ryan CJ,
Chen WT, et al: Detection and characterization of invasive
circulating tumor cells derived from men with metastatic
castration-resistant prostate cancer. Int J Cancer. 134:2284–2293.
2014. View Article : Google Scholar
|
|
4
|
Berx G, Raspé E, Christofori G, Thiery JP
and Sleeman JP: Pre-EMTing metastasis? Recapitulation of
morphogenetic processes in cancer. Clin Exp Metastasis. 24:587–597.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Al-Hajj M, Wicha MS, Benito-Hernandez A,
Morrison SJ and Clarke MF: Prospective identification of
tumorigenic breast cancer cells. Proc Natl Acad Sci USA.
100:3983–3988. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh SK, Hawkins C, Clarke ID, Squire JA,
Bayani J, Hide T, Henkelman RM, Cusimano MD and Dirks PB:
Identification of human brain tumour initiating cells. Nature.
432:396–401. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ricci-Vitiani L, Lombardi DG, Pilozzi E,
Biffoni M, Todaro M, Peschle C and De Maria R: Identification and
expansion of human colon-cancer-initiating cells. Nature.
445:111–115. 2007. View Article : Google Scholar
|
|
8
|
Nagata T, Sakakura C, Komiyama S,
Miyashita A, Nishio M, Murayama Y, Komatsu S, Shiozaki A, Kuriu Y,
Ikoma H, et al: Expression of cancer stem cell markers CD133 and
CD44 in locoregional recurrence of rectal cancer. Anticancer Res.
31:495–500. 2011.PubMed/NCBI
|
|
9
|
Merlos-Suárez A, Barriga FM, Jung P,
Iglesias M, Céspedes MV, Rossell D, Sevillano M, Hernando-Momblona
X, da Silva-Diz V, Muñoz P, et al: The intestinal stem cell
signature identifies colorectal cancer stem cells and predicts
disease relapse. Cell Stem Cell. 8:511–524. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Pirozzi G, Tirino V, Camerlingo R, Franco
R, La Rocca A, Liguori E, Martucci N, Paino F, Normanno N and Rocco
G: Epithelial to mesenchymal transition by TGFβ-1 induction
increases stemness characteristics in primary non small cell lung
cancer cell line. PLoS One. 6:e215482011. View Article : Google Scholar
|
|
11
|
Ribeiro AS and Paredes J: P-cadherin
linking breast cancer stem cells and invasion: A promising marker
to identify an ‘intermediate/metastable’ EMT state. Front Oncol.
4:3712014.
|
|
12
|
Li P, Yang R and Gao WQ: Contributions of
epithelial-mesenchymal transition and cancer stem cells to the
development of castration resistance of prostate cancer. Mol
Cancer. 13:552014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Jennbacken K, Tesan T, Wang W, Gustavsson
H, Damber JE and Welén K: N-cadherin increases after androgen
deprivation and is associated with metastasis in prostate cancer.
Endocr Relat Cancer. 17:469–479. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hulit J, Suyama K, Chung S, Keren R,
Agiostratidou G, Shan W, Dong X, Williams TM, Lisanti MP, Knudsen
K, et al: N-cadherin signaling potentiates mammary tumor metastasis
via enhanced extracellular signal-regulated kinase activation.
Cancer Res. 67:3106–3116. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hui L, Zhang S, Dong X, Tian D, Cui Z and
Qiu X: Prognostic significance of twist and N-cadherin expression
in NSCLC. PLoS One. 8:e621712013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Qian X, Anzovino A, Kim S, Suyama K, Yao
J, Hulit J, Agiostratidou G, Chandiramani N, McDaid HM, Nagi C, et
al: N-cadherin/FGFR promotes metastasis through
epithelial-to-mesenchymal transition and stem/progenitor cell-like
properties. Oncogene. 33:3411–3421. 2014. View Article : Google Scholar :
|
|
17
|
Tanaka H, Kono E, Tran CP, Miyazaki H,
Yamashiro J, Shimomura T, Fazli L, Wada R, Huang J, Vessella RL, et
al: Monoclonal antibody targeting of N-cadherin inhibits prostate
cancer growth, metastasis and castration resistance. Nat Med.
16:1414–1420. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gravdal K, Halvorsen OJ, Haukaas SA and
Akslen LA: A switch from E-cadherin to N-cadherin expression
indicates epithelial to mesenchymal transition and is of strong and
independent importance for the progress of prostate cancer. Clin
Cancer Res. 13:7003–7011. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Thompson DM and Gill GN: The EGF receptor:
Structure, regulation and potential role in malignancy. Cancer
Surv. 4:767–788. 1985.PubMed/NCBI
|
|
20
|
Heimberger AB, Suki D, Yang D, Shi W and
Aldape K: The natural history of EGFR and EGFRvIII in glioblastoma
patients. J Transl Med. 3:382005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Puputti M, Tynninen O, Sihto H, Blom T,
Mäenpää H, Isola J, Paetau A, Joensuu H and Nupponen NN:
Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas. Mol
Cancer Res. 4:927–934. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JC, Vivanco I, Beroukhim R, Huang JH,
Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, et
al: Epidermal growth factor receptor activation in glioblastoma
through novel missense mutations in the extracellular domain. PLoS
Med. 3:e4852006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sharma SV, Bell DW, Settleman J and Haber
DA: Epidermal growth factor receptor mutations in lung cancer. Nat
Rev Cancer. 7:169–181. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marchetti A, Martella C, Felicioni L,
Barassi F, Salvatore S, Chella A, Camplese PP, Iarussi T, Mucilli
F, Mezzetti A, et al: EGFR mutations in non-small-cell lung cancer:
Analysis of a large series of cases and development of a rapid and
sensitive method for diagnostic screening with potential
implications on pharmacologic treatment. J Clin Oncol. 23:857–865.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sholl LM, Yeap BY, Iafrate AJ,
Holmes-Tisch AJ, Chou YP, Wu MT, Goan YG, Su L, Benedettini E, Yu
J, et al: Lung adenocarcinoma with EGFR amplification has distinct
clinicopathologic and molecular features in never-smokers. Cancer
Res. 69:8341–8348. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Dacic S, Flanagan M, Cieply K, Ramalingam
S, Luketich J, Belani C and Yousem SA: Significance of EGFR protein
expression and gene amplification in non-small cell lung carcinoma.
Am J Clin Pathol. 125:860–865. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sainsbury JR, Farndon JR, Needham GK,
Malcolm AJ and Harris AL: Epidermal-growth-factor receptor status
as predictor of early recurrence of and death from breast cancer.
Lancet. 1:1398–1402. 1987.PubMed/NCBI
|
|
28
|
Bhargava R, Gerald WL, Li AR, Pan Q, Lal
P, Ladanyi M and Chen B: EGFR gene amplification in breast cancer:
Correlation with epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activating
mutations. Mod Pathol. 18:1027–1033. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kallioniemi OP, Kallioniemi A, Kurisu W,
Thor A, Chen LC, Smith HS, Waldman FM, Pinkel D and Gray JW: ERBB2
amplification in breast cancer analyzed by fluorescence in situ
hybridization. Proc Natl Acad Sci USA. 89:5321–5325. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dybdal N, Leiberman G, Anderson S, McCune
B, Bajamonde A, Cohen RL, Mass RD, Sanders C and Press MF:
Determination of HER2 gene amplification by fluorescence in situ
hybridization and concordance with the clinical trials
immunohistochemical assay in women with metastatic breast cancer
evaluated for treatment with trastuzumab. Breast Cancer Res Treat.
93:3–11. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zhao J, Wu R, Au A, Marquez A, Yu Y and
Shi Z: Determination of HER2 gene amplification by chromogenic in
situ hybridization (CISH) in archival breast carcinoma. Mod Pathol.
15:657–665. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jenndahl LE, Isakson P and Baeckström D:
c-erbB2-induced epithelial-mesenchymal transition in mammary
epithelial cells is suppressed by cell-cell contact and initiated
prior to E-cadherin downregulation. Int J Oncol. 27:439–448.
2005.PubMed/NCBI
|
|
33
|
Lu J, Guo H, Treekitkarnmongkol W, Li P,
Zhang J, Shi B, Ling C, Zhou X, Chen T, Chiao PJ, et al: 14-3-3zeta
cooperates with ErbB2 to promote ductal carcinoma in situ
progression to invasive breast cancer by inducing
epithelial-mesenchymal transition. Cancer Cell. 16:195–207. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ai M, Liang K, Lu Y, Qiu S and Fan Z:
Brk/PTK6 cooperates with HER2 and Src in regulating breast cancer
cell survival and epithelial-to-mesenchymal transition. Cancer Biol
Ther. 14:237–245. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Clark PA, Iida M, Treisman DM, Kalluri H,
Ezhilan S, Zorniak M, Wheeler DL and Kuo JS: Activation of multiple
ERBB family receptors mediates glioblastoma cancer stem-like cell
resistance to EGFR-targeted inhibition. Neoplasia. 14:420–428.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Abhold EL, Kiang A, Rahimy E, Kuo SZ,
Wang-Rodriguez J, Lopez JP, Blair KJ, Yu MA, Haas M, Brumund KT, et
al: EGFR kinase promotes acquisition of stem cell-like properties:
A potential therapeutic target in head and neck squamous cell
carcinoma stem cells. PLoS One. 7:e324592012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li J, Gong L-Y, Song L-B, Jiang L-L, Liu
L-P, Wu J, Yuan J, Cai J-C, He M, Wang L, et al: Oncoprotein Bmi-1
renders apoptotic resistance to glioma cells through activation of
the IKK-nuclear factor-κB pathway. Am J Pathol. 176:699–709. 2010.
View Article : Google Scholar :
|
|
38
|
Chen T, Xu C, Chen J, Ding C, Xu Z, Li C
and Zhao J: MicroRNA-203 inhibits cellular proliferation and
invasion by targeting Bmi1 in non-small cell lung cancer. Oncol
Lett. 9:2639–2646. 2015.PubMed/NCBI
|
|
39
|
Saeed AI, Sharov V, White J, Li J, Liang
W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, et
al: TM4: A free, open-source system for microarray data management
and analysis. Biotechniques. 34:374–378. 2003.PubMed/NCBI
|
|
40
|
Guo W, Ren D, Chen X, Tu X, Huang S, Wang
M, Song L, Zou X and Peng X: HEF1 promotes epithelial mesenchymal
transition and bone invasion in prostate cancer under the
regulation of microRNA-145. J Cell Biochem. 114:1606–1615. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
42
|
Guan H, Song L, Cai J, Huang Y, Wu J, Yuan
J, Li J and Li M: Sphingosine kinase 1 regulates the Akt/FOXO3a/Bim
pathway and contributes to apoptosis resistance in glioma cells.
PLoS One. 6:e199462011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Nalla AK, Estes N, Patel J and Rao JS:
N-cadherin mediates angiogenesis by regulating monocyte
chemoattractant protein-1 expression via PI3K/Akt signaling in
prostate cancer cells. Exp Cell Res. 317:2512–2521. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Rosenberg EE, Prudnikova TY, Zabarovsky
ER, Kashuba VI and Grigorieva EV: D-glucuronyl C5-epimerase cell
type specifically affects angiogenesis pathway in different
prostate cancer cells. Tumour Biol. 35:3237–3245. 2014. View Article : Google Scholar
|
|
45
|
Allegra A, Alonci A, Penna G, Innao V,
Gerace D, Rotondo F and Musolino C: The cancer stem cell
hypothesis: A guide to potential molecular targets. Cancer Invest.
32:470–495. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Pfeiffer MJ and Schalken JA: Stem cell
characteristics in prostate cancer cell lines. Eur Urol.
57:246–254. 2010. View Article : Google Scholar
|
|
47
|
Hazan RB, Kang L, Whooley BP and Borgen
PI: N-cadherin promotes adhesion between invasive breast cancer
cells and the stroma. Cell Adhes Commun. 4:399–411. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Hazan RB, Phillips GR, Qiao RF, Norton L
and Aaronson SA: Exogenous expression of N-cadherin in breast
cancer cells induces cell migration, invasion, and metastasis. J
Cell Biol. 148:779–790. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Jaggi M, Nazemi T, Abrahams NA, Baker JJ,
Galich A, Smith LM and Balaji KC: N-cadherin switching occurs in
high Gleason grade prostate cancer. Prostate. 66:193–199. 2006.
View Article : Google Scholar
|
|
50
|
Caramel J, Papadogeorgakis E, Hill L,
Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J,
Hutchinson P, Tse G, et al: A switch in the expression of embryonic
EMT-inducers drives the development of malignant melanoma. Cancer
Cell. 24:466–480. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Siegel R, DeSantis C, Virgo K, Stein K,
Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, et al:
Cancer treatment and survivorship statistics, 2012. CA Cancer J
Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Pagliarulo V, Bracarda S, Eisenberger MA,
Mottet N, Schröder FH, Sternberg CN and Studer UE: Contemporary
role of androgen deprivation therapy for prostate cancer. Eur Urol.
61:11–25. 2012. View Article : Google Scholar :
|
|
53
|
Brabletz T: EMT and MET in metastasis:
Where are the cancer stem cells? Cancer Cell. 22:699–701. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bracken CP, Gregory PA, Kolesnikoff N,
Bert AG, Wang J, Shannon MF and Goodall GJ: A double-negative
feedback loop between ZEB1-SIP1 and the microRNA-200 family
regulates epithelial-mesenchymal transition. Cancer Res.
68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Moes M, Le Béchec A, Crespo I, Laurini C,
Halavatyi A, Vetter G, Del Sol A and Friederich E: A novel network
integrating a miRNA-203/SNAI1 feedback loop which regulates
epithelial to mesenchymal transition. PLoS One. 7:e354402012.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Nicoloso MS, Spizzo R, Shimizu M, Rossi S
and Calin GA: MicroRNAs - the micro steering wheel of tumour
metastases. Nat Rev Cancer. 9:293–302. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Siemens H, Jackstadt R, Hünten S, Kaller
M, Menssen A, Götz U and Hermeking H: miR-34 and SNAIL form a
double-negative feedback loop to regulate epithelial-mesenchymal
transitions. Cell Cycle. 10:4256–4271. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Ren D, Wang M, Guo W, Huang S, Wang Z,
Zhao X, Du H, Song L and Peng X: Double-negative feedback loop
between ZEB2 and miR-145 regulates epithelial-mesenchymal
transition and stem cell properties in prostate cancer cells. Cell
Tissue Res. 358:763–778. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Huang S, Guo W, Tang Y, Ren D, Zou X and
Peng X: miR-143 and miR-145 inhibit stem cell characteristics of
PC-3 prostate cancer cells. Oncol Rep. 28:1831–1837.
2012.PubMed/NCBI
|
|
61
|
Gao P, Xing AY, Zhou GY, Zhang TG, Zhang
JP, Gao C, Li H and Shi DB: The molecular mechanism of microRNA-145
to suppress invasion-metastasis cascade in gastric cancer.
Oncogene. 32:491–501. 2013. View Article : Google Scholar
|
